Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TERT Immunohistochemistry as a Surrogate Marker for TERT Promoter Mutations in Infiltrating Gliomas.

Applied immunohistochemistry & molecular morphology : AIMM - 1 Jan 2000

Dono Antonio, Moosvi Ali M, Goli Puneetha S, Bellman Allison C, Aung Phyu P, Esquenazi Yoshua, Ballester Leomar Y

Abstract excerpt

Genomic alterations are critical for the diagnosis, prognostication, and treatment of patients with infiltrating gliomas. Telomerase reverse transcriptase promoter ( TERT p) mutations are among such crucial alterations. Although DNA sequencing is the preferred method for identifying TERT p mutations, it has limitations related to cost and accessibility. We tested telomerase reverse transcriptase (TERT)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to Immunohistochemistry

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Telomerase

Source

Open in PubMed Open full text

Identifiers

PMID: 36952585
DOI: 10.1097/PAI.0000000000001118
PMCID: PMC10393218

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TERT Immunohistochemistry as a Surrogate Marker for TERT Promoter Mutations in Infiltrating Gliomas.PMID 36952585Read ↗

Paradoxical prognostic impact of TERT promoter mutations in gliomas depends on different histological and genetic backgrounds.Semantic proximity Read ↗

The Place and Prognostic Value of TERT Promoter Mutation in Molecular Classification in Grade II-III Glial Tumors and Primary Glioblastomas.Semantic proximity Read ↗

Diagnostic implications of TERT promoter mutation status in diffuse gliomas in a routine clinical setting.Semantic proximity Read ↗

Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.Semantic proximity Read ↗

The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma.Semantic proximity Read ↗

Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas.Semantic proximity Read ↗

Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss.Semantic proximity Read ↗

Predicting the prognosis of glioma patients with TERT promoter mutations and guiding the specific immune profile of immune checkpoint blockade therapy.Semantic proximity Read ↗

Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT.Semantic proximity Read ↗

TERT Mutation Is Accompanied by Neutrophil Infiltration and Contributes to Poor Survival in Isocitrate Dehydrogenase Wild-Type GliomaSemantic proximity Read ↗

When the Ends Are Really the Beginnings: Targeting Telomerase for Treatment of GBM.Semantic proximity Read ↗

Telomerase Reverse Transcriptase Promoter Mutations in A Cohort Of Adult Gliomas - Clinicopathological Correlates.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.